February 10, 2021

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market

Read the Press Release

Other Press Releases

Paris, France, Cambridge (Massachusetts, United States), January 12th, 2026 – 09:00 a.m. CET – Biophytis SA (“the Company”), a pioneering company in the development of transformative therapies impacting longevity, today…

Read more

All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Group and falling within the remit of the Ordinary and…

Read more

Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half…

Read more

BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia Creation of a joint venture in Hong…

Read more

Biophytis to Participate in Four Key Events in Q4 2025 Biophytis announces its participation in four major international events that reflect the complementarity of its development strategy: CF&B Midcap Events…

Read more

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners Biophytis announces major progress in preparing its OBA Phase 2 trial…

Read more